Influx Healthtech IPO Debuts with 38% Premium on NSE SME

Influx Healthtech IPO Listing: Stock Debuts at 38% Premium, Slips into Lower Circuit on First Day Amid Profit Booking

Mumbai, June 25, 2025 — Shares of Influx Healthtech Ltd., a contract manufacturing firm in the healthcare sector, made a volatile debut on the NSE SME platform today.

The stock opened at ₹132.50, delivering a sharp 38.02% listing gain over its issue price of ₹96. However, heavy profit booking during the day pulled the stock down to its lower circuit limit of ₹125.90 before it closed marginally higher at ₹127.35.

Despite the intraday slide, IPO investors ended the day sitting on a healthy 32.66% return on their investment, reflecting continued investor enthusiasm for niche healthcare and wellness companies — even as valuations adjust post-listing.

IPO Snapshot: Robust Demand Across Categories

Influx Healthtech’s ₹58.57 crore IPO was open for subscription from June 18 to June 20, and witnessed massive investor demand, getting oversubscribed 201.35 times overall — among the highest in the SME segment this year.

Here’s how the different investor categories responded:

• Qualified Institutional Buyers (QIBs): Subscribed 137.87 times
• Non-Institutional Investors (NIIs): Subscribed 481.10 times
• Retail Investors: Subscribed 117.68 times

The IPO comprised both a fresh issue of shares and an Offer for Sale (OFS) by existing shareholders.

While the proceeds from the OFS go directly to the selling shareholders, the funds raised from the fresh issue are earmarked for expansion and infrastructure development, positioning the company for its next phase of growth.

Utilization of IPO Proceeds: Strengthening Manufacturing Capabilities

Influx Healthtech plans to channel the fresh capital into capacity building and diversification across its product verticals. Here’s the breakdown of how the ₹58.57 crore raised will be allocated:

• ₹22.60 crore will be invested in setting up a new manufacturing facility for the nutraceutical division, catering to rising demand for dietary supplements and health products.
• ₹11.59 crore is designated for establishing a manufacturing unit for the veterinary food division, tapping into the rapidly expanding pet and animal care segment in India.
• ₹2.76 crore will be used to purchase machinery and equipment for the homecare and cosmetech division, which includes personal care and wellness products.
• The remaining balance will be directed toward general corporate purposes, including working capital, brand building, and administrative enhancements.

These investments are expected to enhance Influx Healthtech’s operational scale, efficiency, and product innovation capabilities, giving it a competitive edge in the growing healthtech and wellness manufacturing sector.

Company Overview: Diversified Product Portfolio in a High-Growth Sector

Incorporated in September 2020, Influx Healthtech Ltd. is a young but rapidly growing contract manufacturer in the healthcare industry.

The company provides end-to-end manufacturing solutions across a diverse range of product categories and sectors, including pharmaceuticals, personal care, dietary supplements, and veterinary products.

The company currently operates three manufacturing units located in Thane, Maharashtra. It has positioned itself as a multi-category manufacturer offering tailored production services to brands and distributors.

Key Product Segments Include:

• Pharmaceuticals: Tablets, capsules, powders, softgels, jellies, and liquid orals
• Nutraceuticals and Sports Nutrition: Gym/sports supplements, protein powders, and dietary products
• Cosmetech and Personal Care: Skincare, haircare, body care, beard care, and oral dispersible films
• Herbal and Ayurvedic Products: Formulations based on traditional medicine and herbal ingredients
• Veterinary and Pet Care Products: Nutritional and health supplements for animals

Influx Healthtech’s business model is designed around contract manufacturing, which allows client companies to outsource production while focusing on branding and marketing. This asset-light approach enables scalability and margin stability.

Financial Performance: Strong Growth Trajectory with Rising Profits

Influx Healthtech has demonstrated impressive financial growth in its short operating history. The company has reported consistent increases in both top-line revenue and bottom-line profitability over the past three fiscal years, underscoring efficient operations and rising market demand.

Key Financial Highlights:

• FY 2023 Net Profit: ₹7.20 crore
• FY 2024 Net Profit: ₹11.22 crore
• FY 2025 Net Profit: ₹13.37 crore
• FY 2025 Revenue: ₹104.99 crore
• Revenue CAGR (last 3 years): Over 17% annually

The steady profit growth and margin expansion signal operational discipline and increasing economies of scale.

Going forward, with added manufacturing capacity and an expanded product portfolio, analysts expect continued double-digit growth.

Investor Outlook: Near-Term Volatility, Long-Term Potential

While the listing pop and subsequent decline in share price reflect typical post-listing volatility and profit booking, the long-term outlook for Influx Healthtech remains positive.

The combination of strong fundamentals, a rapidly growing sector, and a high level of investor interest positions the company well in the SME ecosystem.

Key Factors Supporting Long-Term Growth:

• Expanding health-conscious consumer base across urban and semi-urban India
• Rising demand for contract manufacturing as brands focus on marketing and distribution
• Government support for nutraceutical and healthcare innovation under “Make in India” initiatives
• Scalable infrastructure and diversified revenue streams across pharma, personal care, and veterinary segments

Market experts caution that, like many SME stocks, liquidity constraints and speculative trading may impact short-term movements.

However, investors with a medium to long-term horizon and a higher risk appetite may find Influx Healthtech an attractive bet in the contract manufacturing and healthtech niche.

Final Thoughts

Influx Healthtech’s debut on the NSE SME board has captured attention — both for its strong listing gains and the quick turn into volatility.

Backed by solid fundamentals, a diversified product portfolio, and a clear growth strategy supported by IPO proceeds, the company has laid a solid foundation for future success.

While investors will need to navigate near-term price fluctuations, the long-term story for Influx Healthtech looks promising as it builds its presence in India’s rapidly expanding health and wellness manufacturing landscape.